Ad
related to: synthetic progesterone and breast cancer
Search results
Results From The WOW.Com Content Network
“Understanding any potential links to breast cancer is crucial for informed choices about reproductive health. There has been concern about the impact of progestins on breast cancer risk ...
The increase in breast cancer risk with estrogen and progestogen therapy was shown to be causal with conjugated estrogens plus medroxyprogesterone acetate in the Women's Health Initiative randomized controlled trials. [122] [155] Breast cancer risk with combined estrogen and progestogen therapy may differ depending on the progestogen used.
The conclusions for progesterone were the same in a 2019 meta-analysis of the worldwide epidemiological evidence by the Collaborative Group on Hormonal Factors in Breast Cancer (CGHFBC). [131] Most data on breast density changes and breast cancer risk are with oral progesterone. [126] Data on breast safety with vaginal progesterone are scarce ...
Drospirenone is a progestin and antiandrogen medication which is used in birth control pills to prevent pregnancy and in menopausal hormone therapy, among other uses. [1] [9] It is available both alone under the brand name Slynd and in combination with an estrogen under the brand name Yasmin among others.
The American Cancer Society also stated that "natural" and "bioidentical" hormones present the same risks as synthetic hormone replacement therapy such as heart disease, blood clots, strokes and an increased risk of breast cancer with long-term use.
Breast cancer was increased in women treated with estrogen and a progestin, but not with estrogen and progesterone or estrogen alone. Treatment with unopposed estrogen (i.e., an estrogen alone without a progestogen) is contraindicated if the uterus is still present, due to its proliferative effect on the endometrium .
[65] [64] The combination of natural oral progesterone or the atypical progestin dydrogesterone with estrogen has been associated with less risk of breast cancer than progestins plus estrogen. [ 66 ] [ 67 ] [ 68 ] However, this may simply be an artifact of the low progesterone levels produced with oral progesterone.
Progesterone was studied in the treatment of breast cancer in 1951 and 1952, but with relatively modest results. [158] [159] [160] Megestrol acetate was first studied in the treatment of breast cancer in 1967, and was one of the first progestins to be evaluated for the treatment of this disease. [6] [30] [161] A second study was conducted in 1974.